A new insight in the role of serum albumin and albumin binding capacity for cobalt and copper in ischemic heart disease

  • Sanaa G. Hama AL- Mandalawi Ph. D. Clinical biochemistry, lecturer. Department of clinical analysis –College of Pharmacy Hawler medical university
Keywords: Ischemia modified albumin IMA, ischemic heart disease IHD, Receiver Operating Characteristics ROC.


Background and Objectives: In the presence of ischemia, albumin, undergoes changes resulting in the formation of ischemia modified albumin .Increased serum concentration of ischemia modified albumin that was measured by albumin cobalt binding assay have been found in patients with myocardial ischemia. The purpose of this study was to investigate the relationship between serum albumin concentration and ischemia modified albumin concentration.

Methods: Eighteen patients with stable angina and fifteen who didn’t have any evidence of coronary artery disease , were taken as control subjects, both groups underwent treadimall exercise stress test ,about 15 minuets after treadimall test blood samples were drawn from all the subjects, brought to laboratory to measure the serum ischemia modified albumin concentration and serum albumin concentration.

Results: The study showed a significant difference in ischemia modified albumin between study groups, while no significant difference in serum albumin between both groups. There is a largest Receiver Operating Characteristics(ROC) area for ratio of serum albumin cobalt binding to serum albumin than serum albumin cobalt binding capacity alone.There is a weak positive linear correlation for both cupper and cobalt binding capacity among control subject ,where there is a weak negative linear correlation for both markers among cases with ischemic heart disease (IHD).

Conclusion: The quantification of the role of serum albumin in combination with albumin cobalt binding capacity is expected to differentiate between ischemic heart disease patient and normal subject to larger extent.


Sinha MK, Roy D, Collinson PO, Kaski JG. Role of "Ischemia modified albumin", a new biochemical marker of myocardial ischemia , in early diagnosis of acute coronary syndromes. Emerg Med J 2004;21:29-34

Wu AH. The ischemia-modified albumin biomarker for myocardial ischemia. MLO Med Lab Obs 2003;35:36-40

Jang EC, Jeon HK, Kim SH, Shin DI, Jeong HB, Shin JA, Shin WS. The usefulness of ischemia modified albumin as an early ischemic marker to detect coronary artery disease in patiens with chest pain presenting to the emergency department. Korean J Med 2006;71:620-6

Kim KS, Shin SD, Sony KJ, Suh GJ,Shin S.Prognosis of patients with out-of-hospital cardiac arrest and early biochemical markers: ischemia modified albumin, procalictoin, and S-100 protein.J Korean Soc Emerg Med 2006;17:281-90

Kany SY, Suh JT, Lee W.Clinical usefulness of ischemia modified albumin in acute coronary syndrome. Korean J Lab Med 2005;25:306-11

Roy D, Quiles J, Aldama G, Sinha AP, Arroyo R, Carlos KJ. Ischemia modified albumin for the assessment of patients presenting to the emergency department with acute chest pain but normal or non-diagnostic 12- lead electrocardiograms and negative cardiac troponin T. Int J Cardio 2004; 97:297-301

Sinha MK, Gaze DC, Tippins JR, Collinson PO, Kaski JC. Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003;107:2403-5

Quiles J, Roy D,Gaze D, Garrido IP, Sinha M, Kaski JG. Relation of ischemia modified albumin (IMA) levels following elective angioplasty for stable angina pectoris to duration of balloon-induced myocardial ischemia. Am J Cardiol 2003;92:322-4

Apple FS, Quist HE, Otto AP, Mathews WE, Murakami MM. Release characteristics of cardiac biomarkers and ischemia modified albumin as measured by the albumin cobalt binding test after a marathon race. Clin Chem 2002;48:1097-100

Roy D, Quiles J, Shama R, Sinha M, Avanzas P, Gaze D, Kaski JG. Ischemia modified albumin concentrations in patients with peripheral vascular disease and exercise – induced skeletal muscle ischemia. Clin chem. 2004;50:1656-60

Apple FS, Wu AHB, Mair J.Future biomarkers for detection of ischemia and risk stratification in acute coronay syndrome. Clin Chem 2005;51:810-24

Bar-Or D, Lau E, Winkler JV. Novel assay for cobalt – albumin binding and its potential as marker for myocardial ischemia – apreliminary report. J Emerg Med. 2000; 19:311-15

Sdaronni E, Geo R, Giadon P, Kremastinos DT, Voudris V. Ischemia modified albumin : is this marker of ischemia ready for prime time use?. Hellenic J Cardiol. 2008; 49:260-6

Christenson RH, Dub HS, Sanhai WR . Characteristic of albumin cobalt binding test for assessment of acute coronary syndrome patients: A multicenter study.Clin Chem 2001;47:464-70

Apple FS.Clinical and analytical review of ischemia-modified albumin measured by the albumin cobalt binding test. Adv Clin Chem 2005;39:1-10

Bar-Or D,Winkler JV, Vanbenthuysen K.Reduced albumin-cobalt binding with transient myocardial ischemia after elective percutaneous transluminal coronary angioplasty:a preliminary comparison to creatine kinase-MB,myoglobin and troponin I. Am Heart J 2001;141: 985-91

Rfaai MA, Wright RW, Parvin CA, Gronowski AM, Eby CS. Ischemia – modified albumin increases after skeletal muscle ischemia during arthroscopic knee surgery. Clin Chem Acla 2006;366:264-8

Zapico-Muniz E, Santalo-Bel M, Merce –Muntanola J. Ischemia – modified albumin during skeletal muscle ischemia. Clin Chem 2004;50:1063-5

Marc Van der zee P, Verbeme HJ, Van straalen JP. Ischemia- modified albumin measurements in symptom-limited exercise myocardial perfusion scintigraphy reflect serum albumin concentrations but not myocardial ischemia.Clin Chem 2005;51:1744-6

How to Cite
Hama AL- Mandalawi, S. (2018). A new insight in the role of serum albumin and albumin binding capacity for cobalt and copper in ischemic heart disease. Zanco Journal of Medical Sciences (Zanco J Med Sci), 14(1), 79 - 84. Retrieved from https://zjms.hmu.edu.krd/index.php/zjms/article/view/540
Original Articles